Azacitidine, Venetoclax, Bexmarilimab
Acute Myeloid Leukemia, Myelodysplastic Syndromes, Relapsed/Refractory Aml, Chronic Myelomonocytic Leukemia
Phase I/II
Active Not Recruiting
A Study to Assess Safety, Tolerability and Preliminary Efficacy of Bexmarilimab in Combination With Standard of Care in Patients With Hematological Malignancies
Jun 15, 2022
―
Fp-1305 (Bexmarilimab)
Cancer
Phase I/II
Completed
A Study to Evaluate Safety, Tolerability and Preliminary Efficacy of FP-1305 in Cancer Patients (MATINS)
Oct 23, 2018
―
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases:
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Faron Pharmaceuticals Oy (4FR) have in its pipeline
4FR is currently developing the following drugs: Azacitidine, Venetoclax, Bexmarilimab, Fp-1305 (Bexmarilimab). These drug candidates are in various stages of clinical development as the company works toward FDA approval.